Purchases of prescription drugs before an alcohol-related death: A ten-year follow-up study using linked routine data by Paljarvi, Tapio et al.
1 
 
Purchases of prescription drugs before an alcohol-related death: a ten-year 
follow-up study using linked routine data 
 
Tapio Paljärvi1,2, Pekka Martikainen3,4,5, Taina Leinonen6, Erkki Vuori7, Pia Mäkelä1 
 
1Alcohol, Drugs and Addictions Unit, National Institute for Health and Welfare, Helsinki, Finland 
2Division of Population Medicine, Cardiff University, Cardiff, UK 
3Population Research Unit, University of Helsinki, Finland 
4Centre for Health Equity Studies (CHESS), Stockholm University and Karolinska Institutet, Sweden  
5The Max Planck Institute for Demographic Research, Rostock, Germany 
6Finnish Institute of Occupational Health, Finland 
7Department of Forensic Medicine, University of Helsinki, Finland 
 
Correspondence to: 
Tapio Paljärvi 
Division of Population Medicine 
Cardiff University 
Neuadd Meirionnydd 
Heath Park 
Cardiff CF14 4YS 
United Kingdom 
Tel. +44 29 2068 7804 
Email. paljarvit@cardiff.ac.uk 
  
2 
 
Abstract 
Background: Physician’s intention to prescribe drugs could potentially be used to improve targeting of 
alcohol interventions and enhanced disease management to patients with a high risk of severe alcohol-related 
harm within outpatient settings. Methods: Comparison of ten-year incidence trajectories of 13.8 million 
reimbursed purchases of prescription drugs among 303,057 Finnish men and women of whom 7490 
ultimately died due to alcohol-related causes (Alc+), 14,954 died without alcohol involvement (Alc-), and 
280,613 survived until the end of 2007. Results: 5–10 years before death, 88% of the persons with an Alc+ 
death had received prescription medication, and over two-thirds (69%) had at least one reimbursed purchase 
of drugs for the alimentary tract and metabolism, the cardiovascular system, or the nervous system. Among 
persons with an Alc+ death, the incidence rate (IR) for purchases of hypnotics and sedatives was 1.38 times 
higher (95% confidence interval (CI):1.32,1.44) compared to those with an Alc- death, and 4.07 times higher 
(95%CI:3.92,4.22) compared to survivors; and the IR for purchases of anxiolytics was 1.40 times higher 
(95%CI:1.34,1.47) compared to those with an Alc- death, and 3.61 times higher (95%CI:3.48,3.78) 
compared to survivors. Conclusions: Using physician’s intention to prescribe drugs affecting the alimentary 
tract and metabolism, cardiovascular system and nervous system could potentially be used to flag patients 
who might benefit from screening, targeted interventions or enhanced disease management. In particular, 
patients who are to be prescribed anxiolytics, hypnotics and sedatives, and antidepressants may benefit from 
enhanced interventions targeted to problem drinking. 
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1. Introduction 
It has been shown that problem drinkers seek treatment more likely for somatic symptoms (Jackson et al. 
1995, Nordström et al. 2008, Rehm et al. 2015), and for symptoms of mental health problems such as anxiety 
or depression than for problem drinking per se (Proude et al. 2006, Proodfoot and Teesson 2009, Edlund et 
al. 2012. As a result, even severe forms of problem drinking may go undetected in primary care (Paul et al. 
2014).  
 
The recommended procedure for identifying and treating problem drinking in primary health care settings is 
based on screening, brief interventions, and referral to treatment (SBIRT). However, SBIRT or its 
components are rarely implemented in primary care (Rehm et al. 2016). In particular, referral to treatment 
among those identified as problem drinkers is markedly low, generally being below 20% (Rehm et al. 2016). 
There is thus a need to develop methods that can improve early identification of problem drinking and 
referral to treatment among primary care patients. 
 
Use of electronic health records and other routinely collected healthcare data provides an opportunity to 
develop automated data-mining based algorithms that can prompt and remind physicians and other 
healthcare personnel e.g. to implement SBIRT to high-risk patients. The fact that many of the common 
comorbidities among problem drinkers are managed by medication (Gossop et al. 2007, Smith and Book 
2010) potentially provides an opportunity to improve detection of problem drinking if this information can 
be used as a flag for targeting alcohol interventions and enhanced disease management within outpatient 
settings more effectively. Therefore, the purpose of this study was to explore the feasibility and potential of 
using physicians’ intention to prescribe drugs as a flag for screening problem drinking and targeting 
interventions and enhanced disease management for preventing severe alcohol-related health outcomes 
within outpatient healthcare settings i.e. within primary and secondary care settings. Using longitudinal 
linked routine data on reimbursements of prescription drugs, we aimed to establish incidence trajectories of 
prescription drugs over a ten-year period before death for problem drinkers who ultimately died due to 
alcohol-related causes. We used alcohol-related death as a retrospective marker of severe problem drinking. 
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We used those who died without established alcohol involvement as a reference group. Comparison against 
survivors will provide a general population baseline for reimbursement of prescription drugs over the study 
period.  
2. Data and methods 
2.1 Ethics statement 
The sampling and data linkage were approved by the ethics committee of Statistics Finland (TK-53-1783-
96). 
2.2 Study population 
The original register-based study population consists of an 11% random sample of the population living in 
Finland in 1987–2007. Because our focus was on the healthcare contacts of people who died, we collected an 
additional random sample of deaths occurring during the study period, altogether representing 80% of all 
deaths (the maximum permitted). Routine data from the nation-wide administrative registers of Statistics 
Finland (causes of death and sociodemographic factors) and the Social Insurance Institution of Finland (drug 
reimbursement) were linked to the study data. Statistics Finland carried out the sampling and data linkage 
using a unique personal identity code issued to all Finnish residents and available in the registers used in this 
study. All data were anonymized and de-identified by Statistics Finland prior to analyses.  
 
We included Finnish men and women born in 1943–1977 who were aged 28–64 years at the time of death, or 
for survivors at the end of follow-up in 2005–07. Persons who immigrated or emigrated during the study 
period were excluded (n=9899, including 516 deaths). The final study data consisted of 303,057 individuals 
who either died from alcohol-related causes (“Alc+ deaths”, n=7490) or from other causes (“Alc- deaths”, 
n=14,954), or who survived (n=280,613). 
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2.3 Causes of death  
We used the International Classification of Diseases tenth revision (ICD–10) Finnish modification codes to 
identify causes of death. Web Table S1 shows the ICD–10 codes we used in identifying alcohol-related 
deaths, and the distribution of alcohol-related causes of deaths in our data. In addition to underlying causes 
of death we used also contributory causes to identify e.g. deaths with alcohol intoxication or dependence as a 
contributing factor. Among those who died due to alcohol-related causes, the three most common causes of 
death were mental and behavioral disorders related to alcohol (n=3006, 40%), alcoholic diseases of the 
stomach, liver and pancreas (n=3031, 40%), and accidental poisoning by and exposure to alcohol (n=1101, 
15%). Among the other deceased the three most common causes of death were cancer (n=6032, 40%), 
diseases of the circulatory system (n=4246, 28%), and external causes (n=2206, 15%).   
2.4 Reimbursements for prescription drugs 
All permanent residents of Finland are covered under the National Health Insurance (NHI) scheme, which 
provides partial reimbursement for the cost of outpatient drugs prescribed by a physician. By using the 
information recorded in the NHI register all purchases of reimbursed prescription drugs (drug purchases) 
among the study population were traced back for a period of ten years before death/end of follow-up. We 
used the Anatomical Therapeutic Chemical (ATC) classification to categorize the drugs (Anatomical 
Therapeutic Chemical classification system). Diagnoses of the conditions for which the drugs were 
prescribed for were not available. There were 13.8 million medication reimbursements during the ten-year 
follow-up in our data. 
2.5 Statistical analyses 
We compare cumulative incidence rates for drug purchases over the 10-year period before death/end of 
follow-up. Incidence rate ratios (IRR) are presented with their 95% confidence intervals. We used 
generalized estimating equations (GEE) to estimate the average annual number of purchases of prescription 
drugs, while adjusting for the effects of sex and age at death/end of follow-up. This method also adjusts the 
standard errors for the within-subject clustering of data over repeated measurements. The results from these 
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models are presented as estimated marginal means with their 95% confidence intervals. SAS/STAT 
software’s GENMOD procedure was used to perform the GEE analyses. 
3. Results 
Men were overrepresented among those who ultimately died due to alcohol-related causes (82% men among 
Alc+ deaths) and among those who died without alcohol involvement (64% men among Alc- deaths), 
compared to survivors (50% men). The mean age of death among those with an Alc+ death was 51.9 years 
(SD=7.7) and 53.8 years (SD=7.8) among those with an Alc- death. The mean age at the end of follow-up 
among survivors was 46.6 years (SD=10.2). 
3.1 Purchases of prescription drugs 
The majority (88%) of the persons with an Alc+ death had purchased prescription drugs at least once during 
5 to 10 years before death (Figure S1), and had thus been in contact with the healthcare system already 
several years before death. There was no difference between Alc+ deaths, Alc- deaths and survivors in the 
cumulative proportion of persons who had purchases any prescription drugs. However, the level of use of 
prescription drugs differed across these three groups. The mean annual number of purchases showed that 
those with an Alc+ death (mean=10.1; 95%CI: 9.8-10.5), and Alc- death (mean=12.6; 95%CI:12.3-12.9) 
purchased on average over two-times more prescription drugs compared to survivors (mean=3.8; 95%CI:3.7-
4.0), when sex and age at death/end of follow-up were adjusted for. 
3.2 What type of drugs were purchased? 
Prescription drugs from the ATC categories A (alimentary tract and metabolism), C (cardiovascular system), 
and N (nervous system) were relatively more common among those with an Alc+ death and Alc- death 
compared to survivors (Table S2). Drugs from the category N were most common among Alc+ deaths: 74% 
of them had at least one purchase of drugs from the category N during the follow-up, compared to 69% 
among Alc- deaths and 38% among the survivors. The proportion that category N drugs made of all 
reimbursed drug purchases in these three groups was 40% (307,535/773,682) among Alc+ deaths, 29% (585 
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849/2,032,613) among Alc- deaths, and 19% (2,045,945/11,034,694) among survivors. Overall, purchases 
from the categories A, C and N in the three groups represented 70%, 62% and 44% of all purchases. Based 
on these findings, we focused our further analyses on categories A, C and N. 
3.3 Opportunities to identify at-risk problem drinkers 
To assess the feasibility of using drug prescription information in outpatient settings, it is important to know 
whether a sufficiently large proportion of persons in the target population can be theoretically identified and 
reached before their illness has progressed beyond its optimum intervention stage. For this purpose, Figure 1 
shows cumulative incidence trajectories for the most common prescription drugs within the selected three 
ATC first level categories (A, C, N). We used the period 5 to 10 years before death to represent early 
intervention opportunities and the period 1 to 4 years before death to represent late intervention 
opportunities. 
[Figure 1] 
The most common drugs prescribed within the category A were anti-acid preparations and drugs for treating 
diabetes (Figure 1, panels A–C). About one-third of those with an Alc+ death had been prescribed drugs for 
the alimentary tract and metabolism by the fifth year before death (panel C).  
The most common drugs prescribed in the category C were blood pressure lowering agents and beta-blockers 
(panels D–F). About one-third of those with an Alc+ death had been prescribed drugs for the cardiovascular 
system by the fifth year before death (panel F).  
The previously noted high proportion of drugs from the category N among those with an Alc+ death 
compared to others, was mainly attributable to anxiolytics, hypnotics and sedatives, and antidepressants 
(panels J–L). By the fifth year before death 47% (95%CI:46,49; panel M) of the persons with an Alc+ death 
had been prescribed one of these drugs at least once, which was more than among those with an Alc- death 
(34%, 95%CI:34,36) or among survivors (18%, 95%CI:17-18).  
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All in all, of the persons with an Alc+ death about 69% (95%CI:68,70) had at least one prescription for drugs 
from categories A, C or N by the fifth year before death (panel O), which did not differ from those with an 
Alc- death (67%, 95%CI:66,68), but was higher than among survivors (44%, 95%CI:44,45). 
3.4 Category N drugs 
To quantify the difference in incident purchases of anxiolytics, hypnotics and sedatives, and antidepressants, 
Table 1 shows the incidence rate ratios (IRR) for these three ATC category N drugs among those with an 
Alc+ death, Alc- death, and survivors. Compared to survivors, the crude incidence rate among those with an 
Alc+ death was over three times higher for anxiolytics (IRR=3.61, 95%CI: 3.48, 3.75) and four times higher 
for hypnotics and sedatives (IRR=4.07, 95%CI: 3.92, 4.22). Furthermore, compared to those with an Alc- 
death, those with an Alc+ death had 40% higher (IRR=1.40, 95%CI: 1.34, 1.47) incidence rate for 
anxiolytics, and 38% higher (IRR=1.38, 95%CI: 1.32, 1.44) for hypnotics and sedatives. 
[Table 1] 
To provide further insight of the high incident prescriptions of anxiolytics, hypnotics and sedatives, and 
antidepressants we listed the generic drug names of the most frequently purchased drugs within these 
categories among those with an Alc+ death (Figure 2). These listed drugs represented 80% (95%CI:79,80) of 
all reimbursed purchases within the ATC category N among those with an Alc+ death, which was higher 
than among those with an Alc- death (72%, 95%CI:71,72) and among survivors (67%, 95%CI:67,68). The 
most commonly prescribed benzodiazepines (diazepam, chlordiazepoxide, oxazepam, alprazolam, and 
temazepam) and benzodiazepine related drugs (zopiclone) alone represented 63% (95%CI:63,64) of these 
purchases among those with an Alc+ death, which also was higher than in the other groups (56%, 
95%CI:56,57 and 43%, 95%CI:43,44; respectively). Selective serotonin reuptake inhibitors (fluoxetine and 
citalopram) represented 12% (95%CI:12,13) of all category N drug purchases among those with an Alc+ 
death as well as among those with an Alc- death, which was less than among survivors (20%, 95%CI:19,20). 
[Figure 2] 
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The number of purchases of drugs specifically developed for preventing relapse after detoxification, such as 
disulfiram (2425 purchases over the 10 year period) and naltrexone (26 purchases over the 10 year period) 
among those with an Alc+ death were very low (see Table S3 for a detailed listing of purchases of individual 
drugs in ATC N category).  
4. Discussion 
4.1 Summary of main findings 
We established the cumulative incident trajectories of reimbursed purchases of prescription drugs over a ten-
year period before death among those who ultimately died due to alcohol-related causes in order to assess the 
feasibility of using information on drug prescriptions in outpatient settings as a potential signal to the 
physician or other healthcare personnel to target enhanced disease management for preventing severe 
alcohol-related health outcomes. Based on prescription data, 88% of those who ultimately died due to 
alcohol-related causes were in contact with a physician in outpatient settings in the period 5 to 10 years 
before death and 69% were prescribed drugs from three ATC categories, namely drugs prescribed for 
alimentary tract and metabolism, cardiovascular system, and nervous system. Furthermore, even compared to 
those who died without alcohol involvement, purchases of anxiolytics, hypnotics and sedatives, and 
antidepressants were more common among those who ultimately died due to alcohol-related causes. 
Compared to the general population (survivors) the ten-year combined cumulative incidence rate for these 
drugs was over two times higher among those who ultimately died due to alcohol-related causes. The largest, 
a four-fold, difference was seen for hypnotics and sedatives. Benzodiazepines were the single most common 
group of prescription drugs and zopiclone the single most common drug purchased among those who 
ultimately died due to alcohol-related causes.  
4.2 Methodological considerations 
The advantage of this nation-wide register-based retrospective study was that it enabled us to capture 80% of 
all deaths that occurred in the Finnish general population during the study period, i.e. the data included 
nearly the full population of men and women who died at ages 28–64. Because all information came from 
administrative registers, self-report or non-response bias did not affect our results. 
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The retrospective longitudinal design with information retrieved for each study year enabled us to establish 
group-level trajectories of incident purchases of prescription drugs for 10 years before death/end of follow-
up. Our prescription data captured all outpatient settings, including primary and secondary care, but not 
drugs delivered during hospital inpatient visits. Our analyses focused on information on purchases of 
prescription drugs that were reimbursed by the Finnish NHI scheme and were thus recorded in the 
reimbursed prescription drugs register. This register covers the majority of prescription drugs used to treat 
various illnesses, but excludes some drugs that have not been approved by the Pharmaceuticals Pricing 
Board of the Finnish Ministry of Social Affairs and Health. Purchases of over-the-counter drugs are not 
reimbursed and therefore not included in the register. The reimbursement data available for this study was 
limited to years 1987-2007, which means that potential changes in prescription practices after 2007 were not 
captured by our data. Future research should aim to replicate these finding with a more recent data. 
Our target population was problem drinkers who are at risk of experiencing severe alcohol-related health 
outcomes. However, because we used information on alcohol-related deaths in order to retrospectively define 
problem drinking status, we were not able to identify persons with less severe forms of problem drinking 
who may have different profiles and trajectories of drug prescriptions during their life course.  
An important limitation of our data is that we did not have information on the diagnoses of the conditions 
which the drugs were prescribed for. Therefore we were not able to distinguish the patients treated for 
problem drinking. Taking into account that e.g. many of the ATC category N drugs prescribed to those who 
ultimately died due to alcohol-related causes are commonly used to treat alcohol dependence and symptoms 
of alcohol withdrawal (Wackernah et al. 2014, Zindel and Kranzler 2014, Mirijello et al. 2015), it is likely 
that some of these persons were identified as problem drinkers at the time of prescribing these drugs.  
The potential confounding effect of this can be evaluated against the current evidence on treatment rates 
among problem drinkers in primary care settings. Despite of evidence-based guidelines and 
recommendations for implementing SBIRT in primary care, physicians implement alcohol interventions or 
refer problem drinkers to specialist care relatively rarely. Referral rates for problem drinkers identified in 
primary care settings are generally below 20% (Rehm et al. 2016). The paucity of current levels of 
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implementing SBIRT, whether screening, providing brief interventions, or referring high-risk patients to 
specialist care, therefore indicates that problem drinking needs to be managed much more effectively in 
primary care settings. In other words, even if some of those defined as problem drinkers in our study were 
identified as problem drinkers, it is likely that at group level the treatment of these problem drinkers could 
have been improved e.g. by providing an automated prompt to physicians to implement SBIRT based on 
their intention to prescribe drugs affecting the nervous system.           
4.3 Interpretation of main results 
We identified three ATC 1st level groups of purchased prescription drugs more characteristic to problem 
drinkers than to the general population, namely alimentary tract and metabolism, cardiovascular system, and 
nervous system. Problem drinking is known to have direct adverse effects on these organ groups (Room et al. 
2005), and additionally, well-known co-morbidities of problem drinking are represented in them, e.g. 
depression (Boden and Fergusson 2011) and hypertension (Rehm et al. 2016). Also drugs from categories 
such as anti-infectives for systemic use, musculo-skeletal system, and respiratory system were commonly 
purchased by problem drinkers. While this indicates additional co-morbidities among problem drinkers, and 
thus additional opportunities for identifying problem drinkers, these drug categories were not similarly 
characteristic to problem drinkers as were drugs prescribed for alimentary tract and metabolism, 
cardiovascular system, and nervous system. 
Our finding that the incidence rates for purchases of anxiolytics, hypnotics and sedatives, and antidepressants 
were higher among those who ultimately died due to alcohol-related causes compared to general population 
or those who died without alcohol involvement, may reflect the fact that these drugs are commonly used to 
treat e.g. symptoms of alcohol withdrawal.  
Our results add to the existing evidence (Gossop et al. 2007) by showing that the contact with healthcare 
among persons at risk of severe alcohol-related harm occurs several years before death. We used the time 
period five to ten years before death to indicate opportunities for early detection of problem drinking and 
opportunities for enhanced disease management aimed to prevent disease progression. Based on that cutoff, 
over two-thirds of those who ultimately died due to alcohol-related causes could have been reached for 
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screening, intervention, and enhanced patient management based on physicians’ intention to prescribe drugs 
from the above mentioned three ATC categories. This finding together with an earlier Finnish study on 
hospital admissions among those who later died from alcohol-related causes (Paljärvi et al. 2016) show that 
persons at risk of severe problem drinking were within the reach of health system for preventive 
interventions early on during their life-course. 
Perhaps the most important finding of our study is that the patients at risk of severe alcohol-related health 
outcomes used prescription drugs for which asking about patient’s history of alcohol consumption is 
clinically relevant and medically justified (Ilomäki et al. 2013). In other words, the implication of these 
results to the physician prescribing drugs for alimentary tract and metabolism, cardiovascular system, and 
nervous system is that asking about patient’s alcohol consumption when intending to prescribe these drugs, 
is not only relevant in relation to treating and managing the patient’s current disease but also in terms of 
preventing future severe alcohol-related harm. 
4.3.1 Implications of types of drugs prescribed 
Our results can be put into context by contrasting the drug purchase data against the recommendations for 
treating alcohol use disorders (AUDs). Drugs used to treat AUDs come mainly from the groups of 
antiepileptics, antipsychotics, anxiolytics, hypnotics and sedatives, and antidepressants. It should be noted 
that because we did not have access to the diagnoses used to prescribe these drugs, we do not know whether 
these drugs were e.g. prescribed to treat primary depression or anxiety, or to treat primary AUD.  
Depending on the severity of symptoms, co-morbidities and the stage of treatment, different drugs are 
indicated for treating symptoms of AUDs. In our data, the most commonly purchased drug among problem 
drinkers was zopiclone, which is a non-benzodiazepine hypnotic with an indication of managing alcohol 
withdrawal-related insomnia (Arnedt et al. 2007). Problem drinkers also frequently purchased long-acting 
benzodiazepines (e.g. chlordiazepoxide and diazepam), which are the recommended first-line treatment for 
symptoms of alcohol withdrawal during detoxification (Amato et al. 2010). However, problem drinkers also 
frequently bought short-acting benzodiazepines (e.g. oxazepam and alprazolam). This may be explained by 
the fact that short-acting benzodiazepines are recommended over long-acting ones among patients with liver 
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problems (Addolorato et al. 2016); and deaths due to alcohol-related liver diseases were relatively common 
in our data.  
Anticonvulsants/antiepileptics can be used in treating symptoms of alcohol withdrawal (e.g. carbamazepine, 
clonazepam and valproic acid), but the total number of problem drinkers who purchased these drugs over the 
ten-year period before death was low compared to anxiolytics, and hypnotics and sedatives. Similarly, 
problem drinkers purchased neuroleptics/antipsychotics that can be used e.g. to treat alcohol withdrawal-
related hallucinations or to reduce alcohol craving, but the number of persons using these drugs was also 
low. Therefore, based on the purchases of the drugs and the patterning of purchases of these drugs, it can be 
speculated that these problem drinkers were potentially treated mainly for mild to moderate symptoms of 
alcohol withdrawal and/or AUD between five to ten years before death. 
Among AUD patients, antidepressants are commonly prescribed with the aim of reducing alcohol drinking 
(Zindel and Kranzler 2014). The two most frequently purchased antidepressants among those who ultimately 
died due to alcohol-related death were selective serotonin reuptake inhibitors (SSRIs), and both of these 
(fluoxetine and citalopram) have showed modest efficacy in treating patients with AUD and co-morbid 
depression (Zindel and Kranzler 2014). However, it has been suggested that antidepressants should not be 
used as a stand-alone treatment but should be combined with drugs specifically developed to reduce 
drinking, such as naltrexone (Nunes and Levin 2004, Pettinati et al. 2010). Our data showed that purchases 
of naltrexone (and disulfiram) were practically non-existent over the ten-year period before death among 
problem drinkers. This may reflect physicians’ tendency to prefer other types of drugs over alcohol-specific 
drugs as was shown in the US among substance abuse specialist who preferred prescribing antidepressants 
over naltrexone and disulfiram (Mark et al. 2003). Another potential explanation to this finding is again the 
relatively high prevalence of alcohol-related deaths due to liver diseases among problem drinkers in our data. 
Disulfiram and naltrexone can induce liver injury or increase the risk of liver failure among patients with 
alcoholic liver disease (Addolorato et al. 2016). However, the finding of very low use of alcohol-specific 
drugs warrants further investigation in order to establish why AUD treatment-specific drugs were not used 
(prescribed or purchased) among those problem drinkers who ultimately died due to alcohol-related causes 
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(Mark et al. 2003). This requires access to detailed medical histories of these patients, which we did not 
have. 
5. Conclusions 
Our results suggest that using information of physician’s intention to prescribe drugs in particular for 
alimentary tract and metabolism, cardiovascular system, and nervous system can potentially be used to 
prompt physicians, or other qualified healthcare personnel, to take a more detailed medical history in relation 
to problem drinking and in relation to risk factors for progression of problem drinking. In particular, patients 
presenting with conditions indicating use of anxiolytics, hypnotics and sedatives, and antidepressants are 
likely to benefit from enhanced screening and targeted interventions on problem drinking in outpatient 
healthcare settings (Gossop et al. 2007). Together with earlier evidence from hospital settings (Paljärvi et al. 
2016), these results from outpatient settings show that the prevention of severe alcohol-related harm among 
treatment seeking population calls for improved alcohol screening and disease management across health 
care settings, for example by developing automated electronic health records based applications aimed to 
improve the uptake of alcohol SBIRT.  
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Figure legends 
Figure 1. Cumulative incidence of reimbursed purchases of drugs affecting the alimentary tract and 
metabolism, the cardiovascular system, and the nervous system (panels A to O) separately for 
those who ultimately died due to alcohol-related causes, those who died without alcohol 
involvement, and for the survivors during the ten-year period before death/end of follow-up. 
Individual drug groups shown in the panels are the most common drugs prescribed within their 
respective ATC 1st level category. 
 
Figure 2. Drugs with most reimbursed purchases listed by name (ATC code in the parenthesis). 
Proportion (%) that these drugs make of all purchases within the category of anxiolytics, hypnotics 
and sedatives, and antidepressants among those who had at least one such purchase during the 
follow-up period, separately for those who died due to alcohol-related causes, those who died with 
alcohol involvement, and for the survivors. Error bars represent the 95% confidence interval.  
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Table 1. Incidence rates and their 95% confidence intervals (CI) for anxiolytics, hypnotics and 
sedatives, and antidepressants over the ten-year follow-up period separately for those who died 
due to alcohol-related causes, those who died without alcohol involvement, and survivors, and the 
incidence rate ratios (IRR) compared to survivors. 
  
Cases 
Total 
population 
Incidence per 
100 persons 
(95%CI) 
IRRa 
(95%CI) 
  
IRRb 
(95%CI) 
Anxiolytics       
 Alcohol-related 
deaths 
2940 7490 39.3 (37.9, 
40.7) 
3.61 (3.48, 
3.75) 
 1.40 (1.34, 
1.47) 
 Deaths without 
alcohol involvement 
4190 14954 28.0 (27.2, 
28.9) 
2.58 (2.50, 
2.66) 
 1.00 
 Survivors 30490 280613 10.9 (10.7, 
11.0) 
1.00  0.39 (0.38, 
0.40) 
Hypnotics and sedatives       
 Alcohol-related 
deaths 
2999 7490 40.0 (38.6, 
41.5) 
4.07 (3.92, 
4.22) 
 1.38 (1.32, 
1.44) 
 Deaths without 
alcohol involvement 
4345 14954 29.1 (28.2, 
29.9) 
2.95 (2.86, 
3.05) 
 1.00 
 Survivors 27623 280613 9.8 (9.7, 9.9) 1.00  0.34 (0.33, 
0.35) 
Antidepressants       
 Alcohol-related 
deaths 
3339 7490 44.6 (43.1, 
46.1) 
2.56 (2.47, 
2.65) 
 1.36 (1.30, 
1,42) 
 Deaths without 
alcohol involvement 
4920 14954 32.9 (31.9, 
33.8) 
1.89 (1.84, 
1.95) 
 1.00 
 Survivors 48813 280613 17.4 (17.2, 
17.6) 
1.00  0.53 (0.51, 
0.54) 
Anxiolytics, hypnotics 
and sedatives, or 
antidepressants 
      
 Alcohol-related 
deaths 
4592 7490 61.3 (59.6, 
63.1) 
2.49 (2.41, 
2.56) 
 1.25 (1.21, 
1.30) 
 Deaths without 
alcohol involvement 
7331 14954 49.0 (47.9, 
50.2) 
1.99 (1.94, 
2.04) 
 1.00 
 Survivors 69194 280613 24.7 (24.5, 
24.8) 
1.00  0.50 (0.49, 
0.51) 
a) Survivors as a reference category; b) Those who died without alcohol involvement as a 
reference category 
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